questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Leucémies
Leucémies : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Leucémie
Biopsie
Analyse sanguine
Hémogramme
Cytométrie en flux
Tests génétiques
Globules blancs
Anémie
Plaquettes
Radiographie
IRM
Extension de la maladie
Biopsie médullaire
Cellules leucémiques
Moelle osseuse
Symptômes
5
Fatigue
Fièvre
Infections
Perte de poids
Symptômes
Leucémie
Système immunitaire
Infections
Leucémie
Douleurs osseuses
Cellules leucémiques
Leucémie
Sueurs nocturnes
Symptômes
Leucémie
Prévention
5
Prévention
Facteurs de risque
Leucémie
Facteurs de risque
Radiations
Maladies génétiques
Tabagisme
Risque
Leucémie
Infections virales
Virus d'Epstein-Barr
Leucémie
Alimentation
Prévention
Santé générale
Traitements
5
Chimiothérapie
Radiothérapie
Greffe de moelle osseuse
Chimiothérapie
Types de leucémie
Efficacité
Greffe de moelle osseuse
Cellules souches
Traitement
Effets secondaires
Chimiothérapie
Nausées
Radiothérapie
Traitement
Complications
Complications
5
Complications
Infections
Saignements
Coagulation sanguine
Saignements
Leucémie
Problèmes cardiaques
Traitements
Leucémie
Infections
Système immunitaire
Leucémie
Douleurs chroniques
Traitements
Leucémie
Facteurs de risque
5
Facteurs de risque
Radiations
Antécédents familiaux
Troubles génétiques
Syndrome de Down
Risque
Antécédents
Chimiothérapie
Risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémies : Questions médicales les plus fréquentes",
"headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémies"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par type histologique",
"url": "https://questionsmedicales.fr/mesh/D009370",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par type histologique",
"code": {
"@type": "MedicalCode",
"code": "D009370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde",
"alternateName": "Leukemia, Myeloid",
"url": "https://questionsmedicales.fr/mesh/D007951",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myéloïde",
"alternateName": "Leukemia, Myeloid, Acute",
"url": "https://questionsmedicales.fr/mesh/D015470",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D015470",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myélomonocytaire",
"alternateName": "Leukemia, Myelomonocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015479",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myélomonocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.520"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Leucémies",
"alternateName": "Leukemia",
"code": {
"@type": "MedicalCode",
"code": "D007938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kumaran Mudaliar",
"url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA."
}
},
{
"@type": "Person",
"name": "Gregor Eisenwort",
"url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Irina Sadovnik",
"url": "https://questionsmedicales.fr/author/Irina%20Sadovnik",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Alexandra Keller",
"url": "https://questionsmedicales.fr/author/Alexandra%20Keller",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Daniela Berger",
"url": "https://questionsmedicales.fr/author/Daniela%20Berger",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.",
"datePublished": "2022-12-15",
"url": "https://questionsmedicales.fr/article/36546488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/phcfm.v14i1.3736"
}
},
{
"@type": "ScholarlyArticle",
"name": "Granulomatous prostatitis: mimicking locally advanced prostate adenocarcinoma.",
"datePublished": "2023-10-17",
"url": "https://questionsmedicales.fr/article/37850783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.23750/abm.v94i5.13751"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis.",
"datePublished": "2022-08-12",
"url": "https://questionsmedicales.fr/article/35964881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2022.08.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate organogenesis.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35726824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1242/dev.200394"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostatic Urethral Length as a Predictor for Surgery in Benign Prostatic Hyperplasia.",
"datePublished": "2023-03-10",
"url": "https://questionsmedicales.fr/article/36974872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i3.4613"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucémies",
"item": "https://questionsmedicales.fr/mesh/D007938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémies - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémies",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémies",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémies",
"description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémies",
"description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémies",
"description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémies",
"description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémies",
"description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Prostate#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une leucémie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une leucémie lors des tests ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie médullaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme de leucémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées à la leucémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques."
}
},
{
"@type": "Question",
"name": "Les sueurs nocturnes sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la leucémie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de leucémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles causer la leucémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux de la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une greffe de moelle osseuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements, et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles infections sont fréquentes chez les patients leucémiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles causer des douleurs chroniques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de leucémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de leucémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les troubles génétiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
└─
Leucémie myéloïde
Leukemia, Myeloid
D007951 -
C04.557.337.539
└─└─
Leucémie aigüe myéloïde
Leukemia, Myeloid, Acute
D015470 -
C04.557.337.539.275
└─└─
Leucémie aigüe myélomonocytaire
Leukemia, Myelomonocytic, Acute
D015479 -
C04.557.337.539.520
└─└─└─
Leucémie aiguë à basophiles
Leukemia, Basophilic, Acute
D015471 -
C04.557.337.539.275.125
└─└─└─
Leucémie aigüe à éosinophiles
Leukemia, Eosinophilic, Acute
D015472 -
C04.557.337.539.275.300
└─└─└─
Leucémie aigüe mégacaryoblastique
Leukemia, Megakaryoblastic, Acute
D007947 -
C04.557.337.539.275.450
└─└─└─
Leucémie aigüe monoblastique
Leukemia, Monocytic, Acute
D007948 -
C04.557.337.539.275.484
└─└─└─
Leucémie aiguë promyélocytaire
Leukemia, Promyelocytic, Acute
D015473 -
C04.557.337.539.275.700
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
2 publications dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
1 publication dans cette catégorie
Affiliations :
Publications dans "Leucémies" :
Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro...
To determine the correlation between the PSA, IPSS and PV in men of African descent....
This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital....
The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t...
The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w...
This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...
We report the case of a 63-year-old male who came to the urology clinic with an increasing value of the prostate specific antigen and an asymmetrical enlargement at the digital rectal examination. The...
To compare the cost effectiveness of prostatic artery embolization (PAE) with that of transurethral resection of the prostate (TURP) for the treatment of medically refractory benign prostatic hyperpla...
A cost-effectiveness analysis with Markov modeling was performed, comparing the clinical course after PAE with that after TURP for 3 years. Probabilities were obtained from the available literature, a...
Base case calculation showed comparable outcomes (PAE, 2.845 QALY; TURP, 2.854 QALY), with a cost difference of $3,104 (PAE, $2,934; TURP, $6,038). The incremental cost-effectiveness ratio was $360,24...
PAE is a cost-effective strategy to treat medically refractory BPH, resulting in comparable health benefits at a lower cost than that of TURP even when accounting for extreme alterations in adverse ev...
Prostate organogenesis begins during embryonic development and continues through puberty when the prostate becomes an important exocrine gland of the male reproductive system. The specification and gr...
Benign prostatic hyperplasia is associated with structural and morphological changes including elongation of prostatic urethral length. The aim of our study was to assess whether prostatic urethral le...
This prospective observational study was conducted over a 12-months duration. All the patients who presented with lower urinary tract symptoms secondary to benign prostatic hyperplasia were evaluated ...
A total of 153 patients were included in the study. Eighty-three (54.2%) patients underwent surgery during the study period. Prostate volume, intravesical prostatic protrusion, post-void residual volu...
BPH patients with longer PUL may require surgical management. PUL measured by TRUS may be a predicting factor for the need of surgery in BPH Keywords: Benign prostatic hyperplasia; lower urinary tract...
Biomarkers of DNA damage repair deficiency provide opportunities for personalized treatment with immunotherapy. However, there is limited research on the immune microenvironment of adeno-neuroendocrin...
A retrospective medical record review of 66 patients with prostate cancer (PCa) was performed. PCa samples from the 66 patients were analyzed using immunohistochemical staining for the detection of ch...
Twenty patients presented with adeno-NEPC, whereas 46 presented with adeno-PCa. The median age of patients at PCa diagnosis was 67.86 ± 7.05 years (68.65 ± 7.23 years, adeno-NEPC; 67.52 ± 7.02 years, ...
Our study revealed clinicopathological manifestations of adeno-NEPC and some possible predictive factors significantly associated with better outcomes in patients with adeno-NEPC. These findings might...
The purpose of the study was to evaluate the diagnostic significance of two new and a few clinical markers for prostate cancer (PCa) at various prostate volumes (PV)....
The study subjects were divided into two groups. Among them, there were 70 cases in the PV ≤30 ml group (benign prostatic hyperplasia [BPH]: 32 cases, PCa: 38 cases) and 372 cases in the PV > 30 ml gr...
In the PV ≤30 ml group, the diagnostic parameters based on prostate-specific antigen (PSA) had a decreased diagnostic significance for PCa. In the PV > 30 ml group, PSAD (AUC = 0.709), AVR (AVR = Age/...
Choosing appropriate indicators for different PVs could contribute to the early screening and diagnosis of PCa. The difference in the diagnostic value of two new indicators (A-PSAD and AVR), and PSAD ...
Holmium laser enucleation of the prostate (HoLEP) is a size-independent surgical option for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) with excellent, durable ...
This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population....
A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, an...
140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± stand...
The PHI test improves PCa detection compared to tPSA in our population....
We compare Prostate Health Index, Prostate Health Index density, and PSA density in predicting clinically significant prostate cancer in MRI-guided prostate biopsy....
This is a multicenter evaluation of prospectively maintained prostate biopsy databases at 10 urology centers. Men with Prostate Health Index and MRI-guided targeted and systematic prostate biopsy perf...
A total of 1,215 men were analyzed. Prostate cancer and clinically significant prostate cancer were diagnosed in 51% (617/1,215) and 35% (422/1,215) of men, respectively. Clinically significant prosta...
Prostate Health Index density outperformed Prostate Health Index or PSA density in clinically significant prostate cancer detection in men with multiparametric MRI performed, and further reduced unnec...
